Does Posttransplant Anemia at 6 Months Affect Long-term Outcome of Live-donor Kidney Transplantation? A Single-center Experience

Overview

Journal Clin Exp Nephrol

Publisher Springer

Specialty Nephrology

Date 2009 Apr 8

PMID 19350348

Citations 10

Authors

Osama Gheith

Ehab Wafa

Nabil Hassan

Amani Mostafa

Hussein A Sheashaa

Khaled Mahmoud

Ahmed Shokeir

Mohamed A Ghoneim

Affiliations

Soon will be listed here.

Abstract

Background/aims: Posttransplantation anemia (PTA) frequently occurs. We aimed to assess the prevalence of anemia at 6 months of transplantation in patients under different protocols of immunosuppression, and to determine the impact of anemia on long-term patient and graft survival.

Methods: We included 832 renal transplant recipients who were categorized at 6 months according to hemoglobin (Hb) level into two groups: the first group, with Hb >13 g/dl in males and >12 g/dl in females (group I, 385 cases); and the second group, with Hb <13 g/dl in males and <12 g/dl in females (group II, 447 cases). We compared the two groups regarding posttransplant complications as well as patient and graft survival.

Results: Although there was no significant difference between the two groups regarding acute rejection episodes, chronic allograft nephropathy was significantly higher in the anemic group. Other posttransplant medical complications were comparable in both groups. Graft survival was significantly higher in the nonanemic group. However, no difference in patient survival was detected.

Conclusion: From this study, we can conclude that prevalence of PTA is high, especially in females and those receiving calcineurine inhibitors (CNI) and mycophenolate mofetil (MMF), and that it was associated with poorer graft outcome but with no effect on patient survival.

Citing Articles

A systematic review and meta-analysis of factors contributing to post-kidney transplant anemia and the effect of erythropoietin-stimulating agents.

Chienwichai K, Phirom S, Wuttiputhanun T, Leelahavanichkul A, Townamchai N, Avihingsanon Y Syst Rev. 2024; 13(1):278.

PMID: 39533400 PMC: 11556001. DOI: 10.1186/s13643-024-02709-8.

Immunosuppressive therapy for Vogt-Koyanagi-Harada disease: a retrospective study and review of literature.

Rahman N, Artiaga J, Bouras K, Luis J, Rees A, Westcott M J Ophthalmic Inflamm Infect. 2023; 13(1):27.

PMID: 37204477 PMC: 10199158. DOI: 10.1186/s12348-023-00333-6.

Anemia after kidney transplantation.

Guzzo I, Atkinson M Pediatr Nephrol. 2022; 38(10):3265-3273.

PMID: 36282330 PMC: 10126210. DOI: 10.1007/s00467-022-05743-7.

Anemia in Pediatric Kidney Transplant Recipients-Etiologies and Management.

Kouri A, Balani S, Kizilbash S Front Pediatr. 2022; 10:929504.

PMID: 35795334 PMC: 9251011. DOI: 10.3389/fped.2022.929504.

Post renal transplant anemia: severity, causes and their association with graft and patient survival.

Schechter A, Gafter-Gvili A, Shepshelovich D, Rahamimov R, Gafter U, Mor E BMC Nephrol. 2019; 20(1):51.

PMID: 30760235 PMC: 6374899. DOI: 10.1186/s12882-019-1244-y.

References

Yorgin P, Belson A, Sanchez J, Al Uzri A, Sarwal M, Bloch D . Unexpectedly high prevalence of posttransplant anemia in pediatric and young adult renal transplant recipients. Am J Kidney Dis. 2002; 40(6):1306-18. DOI: 10.1053/ajkd.2002.36910. View

Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer W, Curhan G . Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol. 2006; 17(3):889-99. DOI: 10.1681/ASN.2005090955. View

Winkelmayer W, Chandraker A . Pottransplantation anemia: management and rationale. Clin J Am Soc Nephrol. 2008; 3 Suppl 2:S49-55. PMC: 3152277. DOI: 10.2215/CJN.03290807. View

Winkelmayer W, Kewalramani R, Rutstein M, Gabardi S, Vonvisger T, Chandraker A . Pharmacoepidemiology of anemia in kidney transplant recipients. J Am Soc Nephrol. 2004; 15(5):1347-52. DOI: 10.1097/01.asn.0000125551.59739.2e. View

Gouva C, Nikolopoulos P, Ioannidis J, Siamopoulos K . Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 2004; 66(2):753-60. DOI: 10.1111/j.1523-1755.2004.00797.x. View

Augustine J, Knauss T, Schulak J, Bodziak K, Siegel C, Hricik D . Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant. 2004; 4(12):2001-6. DOI: 10.1111/j.1600-6143.2004.00612.x. View

Locatelli F, Pisoni R, Combe C, Bommer J, Andreucci V, Piera L . Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2003; 19(1):121-32. DOI: 10.1093/ndt/gfg458. View

Vanrenterghem Y . Anaemia after renal transplantation. Nephrol Dial Transplant. 2004; 19 Suppl 5:V54-58. DOI: 10.1093/ndt/gfh1057. View

Shah N, Al-Khoury S, Afzali B, Covic A, Roche A, Marsh J . Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors. Transplantation. 2006; 81(8):1112-8. DOI: 10.1097/01.tp.0000205174.97275.b5. View

10.

Vlagopoulos P, Tighiouart H, Weiner D, Griffith J, Pettitt D, Salem D . Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol. 2005; 16(11):3403-10. DOI: 10.1681/ASN.2005030226. View

11.

Mitsnefes M, Subat-Dezulovic M, Khoury P, Goebel J, Strife C . Increasing incidence of post-kidney transplant anemia in children. Am J Transplant. 2005; 5(7):1713-8. DOI: 10.1111/j.1600-6143.2005.00919.x. View

12.

Lorenz M, Winkelmayer W, Horl W, Sunder-Plassmann G . Anaemia after renal transplantation. Eur J Clin Invest. 2005; 35 Suppl 3:89-94. DOI: 10.1111/j.1365-2362.2005.01535.x. View

13.

Rigatto C, Parfrey P, Foley R, Negrijn C, Tribula C, Jeffery J . Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol. 2002; 13(4):1084-1090. DOI: 10.1681/ASN.V1341084. View

14.

Djamali A, Becker Y, Simmons W, Johnson C, Premasathian N, Becker B . Increasing hematocrit reduces early posttransplant cardiovascular risk in diabetic transplant recipients. Transplantation. 2003; 76(5):816-20. DOI: 10.1097/01.TP.0000084872.26360.C5. View

15.

Offermann G . Immunosuppression for long-term maintenance of renal allograft function. Drugs. 2004; 64(12):1325-38. DOI: 10.2165/00003495-200464120-00005. View

16.

Roger S, McMahon L, Clarkson A, Disney A, Harris D, Hawley C . Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol. 2003; 15(1):148-56. DOI: 10.1097/01.asn.0000102471.89084.8b. View

17.

Kovesdy C, Trivedi B, Kalantar-Zadeh K, Anderson J . Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int. 2006; 69(3):560-4. DOI: 10.1038/sj.ki.5000105. View

18.

Winkelmayer W, Lorenz M, Kramar R, Horl W, Sunder-Plassmann G . Percentage of hypochromic red blood cells is an independent risk factor for mortality in kidney transplant recipients. Am J Transplant. 2004; 4(12):2075-81. DOI: 10.1046/j.1600-6143.2004.00604.x. View

19.

Chadban S, Baines L, Polkinghorne K, Jefferys A, Dogra S, Kanganas C . Anemia after kidney transplantation is not completely explained by reduced kidney function. Am J Kidney Dis. 2007; 49(2):301-9. DOI: 10.1053/j.ajkd.2006.11.034. View

20.

Molnar M, Czira M, Ambrus C, Szeifert L, Szentkiralyi A, Beko G . Anemia is associated with mortality in kidney-transplanted patients--a prospective cohort study. Am J Transplant. 2007; 7(4):818-24. DOI: 10.1111/j.1600-6143.2006.01727.x. View